Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%

NCT03808480 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

22

Enrollment

OTHER_GOV

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: CA and Nivolumab

Sponsor

National Cancer Center, Korea